Antimicrobials and AMR
The Antimicrobials and AMR team unites Liverpool’s strengths in clinical pharmacology, therapeutics, data sciences and population health to address the global threat posed by antimicrobial resistance (AMR).
Antimicrobial therapy underpins almost all complex medical interventions. Antimicrobial resistance (AMR) threatens human, animal, and environmental health and is recognised as one of the most urgent global health threats. Annually, an estimated 4.95 million deaths are associated with AMR.
The UN General Assembly has called for urgent, coordinated international efforts to promote the responsible use of antimicrobials, boost research and development for new drugs, vaccines, and diagnostics, and strengthen global surveillance.
At the University of Liverpool, we lead the Centres for Antimicrobial Optimisation Network (CAMO-Net), a Wellcome-funded multidisciplinary global collaborative research network focused on addressing the impact of antimicrobial resistance on human health.
We are also a host institution for the Fleming Fund Fellowship Scheme, offering mentorship and training to professionals engaged in antimicrobial resistance from Nigeria and Sierra Leone.
-
Explore the work of the group which covers preclinical and early phase clinical support to develop new drugs.
-
This group is focused on tackling antimicrobial resistance and playing a pivotal role in developing strategies to manage infectious diseases around the world.
-
This research network is dedicated to optimising antibiotic treatment with a vision focused on equity, collaboration and evidence-based practice.
-
Find out more about the Antimicrobials and AMR team.